ReviewF1000prime reports2014
Advances in understanding Pseudomonas.
Review in F1000prime reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Phosphatidylserine externalization and procoagulant activation of erythrocytes induced by Pseudomonas aeruginosa virulence factor pyocyanin.Journal of cellular and molecular medicine · 2016Trial
- Beyond the Usual Suspects: EmergingInternational journal of molecular sciences · 2026Review
- Ciprofloxacin resistance rapidly declines in nfxB defective clinical strains of Pseudomonas aeruginosa.Nature communications · 2025Article
- Ceftazidime-avibactam use selects multidrug-resistance and prevents designing collateral sensitivity-based therapies against Pseudomonas aeruginosa.Nature communications · 2025Article
- Crosstalk between Pseudomonas aeruginosa antibiotic resistance and virulence mediated by phenylethylamine.Microbial biotechnology · 2023Article
- Tackling antibiotic resistance by inducing transient and robust collateral sensitivity.Nature communications · 2023Article
- Rapid Phenotypic Convergence towards Collateral Sensitivity in Clinical Isolates of Pseudomonas aeruginosa Presenting Different Genomic Backgrounds.Microbiology spectrum · 2023Article
- The MexJK Multidrug Efflux Pump Is Not Involved in Acquired or Intrinsic Antibiotic Resistance inInternational journal of molecular sciences · 2022Article
- Article
- Convergent phenotypic evolution towards fosfomycin collateral sensitivity of Pseudomonas aeruginosa antibiotic-resistant mutants.Microbial biotechnology · 2022Article
- The MarR-Type Regulator PA3458 Is Involved in Osmoadaptation Control inInternational journal of molecular sciences · 2021Article
- The hypothetical periplasmic protein PA1624 from Pseudomonas aeruginosa folds into a unique two-domain structure.Acta crystallographica. Section F, Structural biology communications · 2020Article
- The Concerted Action of Two B3-Like Prophage Genes Excludes Superinfecting Bacteriophages by Blocking DNA Entry into Pseudomonas aeruginosa.Journal of virology · 2020Article
- Untargeted LC-MS Metabolomics Differentiates Between Virulent and Avirulent Clinical Strains ofBiomolecules · 2020Article
- Pseudomonas azotoformans Belonging to Pseudomonas fluorescens Group as Causative Agent of Blue Coloration in Carcasses of Slaughterhouse Rabbits.Animals : an open access journal from MDPI · 2020Article
- Novel Inducers of the Expression of Multidrug Efflux Pumps That TriggerAntimicrobial agents and chemotherapy · 2019Article
- Analysis of theAntimicrobial agents and chemotherapy · 2019Article
- Mutational Evolution ofFrontiers in genetics · 2018Article
- Identification of amBio · 2017Article
- Isolation, Identification, and Antimicrobial Susceptibility of Bacteria Associated with Waterpipe Contaminants in Selected Area of Saudi Arabia.BioMed research international · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomonas aeruginosa, the type species of pseudomonads, is an opportunistic pathogen that colonizes a wide range of niches. Current genome sequencing projects are producing previously inconceivable detail about the population biology and evolution of P. aeruginosa. Its pan-genome has a larger genetic repertoire than the human genome, which explains the broad metabolic capabilities of P. aeruginosa and its ubiquitous distribution in aquatic habitats. P. aeruginosa may persist in the airways of individuals with cystic fibrosis for decades. The ongoing whole-genome analyses of serial isolates from cystic fibrosis patients provide the so far singular opportunity to monitor the microevolution of a bacterial pathogen during chronic infection over thousands of generations. Although the evolution in cystic fibrosis lungs is neutral overall, some pathoadaptive mutations are selected during the within-host evolutionary process. Even a single mutation may be sufficient to generate novel complex traits provided that predisposing mutational events have previously occurred in the clonal lineage.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.